| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3192522 | Annals of Allergy, Asthma & Immunology | 2010 | 12 Pages |
Abstract
Bradykinin is the mediator of swelling in types I and II HAE and is overproduced because of a deficiency in C1 inhibitor. Inhibition of bradykinin formation by novel agents can provide targeted therapeutic approaches that address the pathophysiologic abnormalities.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Allen P. MD, Kusumam PhD,